Entrada Therapeutics (TRDA) Earnings Date, Estimates & Call Transcripts $18.80 +0.75 (+4.16%) (As of 11/22/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Entrada Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Entrada Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataTRDA Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.TRDA Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Chaikin Analytics50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could spell disaster for some of America's favorite tech companies. You can watch for it for free, right here. Entrada Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242-$0.73-$0.40-$0.57Q2 20242-$0.05$0.77$0.36Q3 20242-$0.88-$0.47-$0.68Q4 20242-$0.69-$0.66-$0.68FY 20248-$2.35-$0.76-$1.56Q1 20252-$0.86-$0.72-$0.79Q2 20252-$0.91-$0.75-$0.83Q3 20252-$0.94-$0.79-$0.87Q4 20252-$1.02-$0.69-$0.86FY 20258($3.73)($2.95)($3.34) Entrada Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 3/12/2025(Estimated)------- 8/13/2024-$0.65$1.55+$0.90$1.55$55.00M$94.69M 5/7/2024Q1 2024-$0.38$0.68+$1.06$0.68$25.00M$59.12M 3/13/2024Q4 2023-$0.07-$0.29 -$0.22-$0.29$27.82M$41.85M 11/7/2023Q3 2023-$0.55$1.02+$1.57$1.02$16.31M$43.74M 8/8/2023Q2 2023-$0.43-$0.78 -$0.35-$0.78$19.56M$18.17M 5/10/2023Q1 2023-$0.77-$0.21+$0.56-$0.21-$25.26M Get the Latest News and Ratings for TRDA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Entrada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 3/6/2023Q4 2022-$0.83-$0.79+$0.04-$0.79-- Entrada Therapeutics Earnings - Frequently Asked Questions When is Entrada Therapeutics's earnings date? Entrada Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 12th, 2025 based off last year's report dates. Learn more on TRDA's earnings history. How much revenue does Entrada Therapeutics generate each year? Entrada Therapeutics (NASDAQ:TRDA) has a recorded annual revenue of $129.01 million. How much profit does Entrada Therapeutics generate each year? Entrada Therapeutics (NASDAQ:TRDA) has a recorded net income of -$6.68 million. TRDA has generated $1.59 earnings per share over the last four quarters. What is Entrada Therapeutics's price-to-earnings ratio? Entrada Therapeutics (NASDAQ:TRDA) has a trailing price-to-earnings ratio of 11.82 and a forward price-to-earnings ratio of 17.57. What is Entrada Therapeutics's EPS forecast for next year? Entrada Therapeutics's earnings are expected to decrease from $1.07 per share to ($3.38) per share in the next year. ` More Earnings Resources from MarketBeat Related Companies SpringWorks Therapeutics Earnings Date ACADIA Pharmaceuticals Earnings Date Amneal Pharmaceuticals Earnings Date Zai Lab Earnings Date Catalyst Pharmaceuticals Earnings Date Iovance Biotherapeutics Earnings Date Scholar Rock Earnings Date Twist Bioscience Earnings Date Protagonist Therapeutics Earnings Date Janux Therapeutics Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings Report 50-year Wall Street legend: “Sell this tech stock NOW” (Ad)Something very strange is happening to U.S. stocks following President Trump's victory... And this could spell disaster for some of America's favorite tech companies. You can watch for it for free, right here. This page (NASDAQ:TRDA) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNvidia’s world of pain awaitsThe Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entrada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
